Trial Profile
A Phase 1 Trial of PT2977, a HIF-2α Inhibitor, in Patients With clear cell renal cell carcinoma (ccRCC).
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Dec 2017
Price :
$35
*
At a glance
- Drugs Belzutifan (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 27 Dec 2017 New trial record